Tumor Biology

, Volume 34, Issue 1, pp 515–520 | Cite as

Overexpression of GOLPH3 is associated with poor clinical outcome in gastric cancer

  • Ben-Shun Hu
  • Hao Hu
  • Cong-Yuan Zhu
  • Yuan-Long Gu
  • Jian-Ping Li
Research Article


This study aims to investigate the expression and significance of GOLPH3 in human gastric cancer progression and prognosis. Using immunohistochemistry (IHC) and real-time reverse transcriptase polymerase chain reaction assay, we identified abnormally elevated expression of GOLPH3 in gastric cancer tissues compared to paired normal stomach mucosa tissues in 40 patients. In addition, the enzyme-linked immunosorbent assay (ELISA) was used to quantify serum GOLPH3 concentrations in the same 40 gastric cancer patients and 40 healthy individuals. ELISA revealed significantly higher serum concentrations of GOLPH3 in gastric cancer patients compared to healthy individuals (p = 0.002). In order to investigate the correlations between GOLPH3 and the clinicopathological features of gastric cancer, the expression of GOLPH3 in 123 gastric cancer patients were detected by IHC, and the results showed that overexpression of GOLPH3 was associated with the size of the tumor (p = 0.013), histological grade (p = 0.002), depth of invasion (p < 0.001), lymph node metastasis (p < 0.001), distant metastasis (p = 0.018), and TNM stage (p < 0.001). Kaplan–Meier survival analysis showed that high GOLPH3 expression exhibited a significant correlation with poor prognosis for gastric cancer patients. Further, Cox multivariate analysis indicated that GOLPH3 expression level was an independent prognostic factor for patients after radical resection. In conclusion, the overexpression of GOLPH3 is closely related to the progression of gastric cancer and might be regarded as an independent predictor of poor prognosis for gastric cancer.


GOLPH3 Gastric cancer Prognosis Survival Diagnosis 


Conflict of interest



  1. 1.
    Hohenberger P, Gretschel S. Gastric cancer. Lancet. 2003;362:305–15. doi: 10.1016/S0140-6736(03)13975-X.PubMedCrossRefGoogle Scholar
  2. 2.
    Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E. Gastric cancer. Crit Rev Oncol Hematol. 2009;71:127–64. doi: 10.1016/j.critrevonc.2009.01.004.PubMedCrossRefGoogle Scholar
  3. 3.
    Sorkin A, von Zastrow M. Endocytosis and signalling: intertwining molecular networks. Nat Rev Mol Cell Biol. 2009;10:609–22. doi: 10.1038/nrm2748.PubMedCrossRefGoogle Scholar
  4. 4.
    Dippold HC, Ng MM, Farber-Katz SE, Lee SK, Kerr ML, Peterman MC, Sim R, Wiharto PA, Galbraith KA, Madhavarapu S, Fuchs GJ, Meerloo T, Farquhar MG, Zhou H, Field SJ. GOLPH3 bridges phosphatidylinositol-4-phosphate and actomyosin to stretch and shape the Golgi to promote budding. Cell. 2009;139:337–51. doi: 10.1016/j.cell.2009.07.052.PubMedCrossRefGoogle Scholar
  5. 5.
    Bell AW, Ward MA, Blackstock WP, Freeman HN, Choudhary JS, Lewis AP, Chotai D, Fazel A, Gushue JN, Paiement J, Palcy S, Chevet E, Lafrenière-Roula M, Solari R, Thomas DY, Rowley A, Bergeron JJ. Proteomics characterization of abundant Golgi membrane proteins. J Biol Chem. 2001;276:5152–65. doi: 10.1074/jbc.M006143200.PubMedCrossRefGoogle Scholar
  6. 6.
    Wu CC, Taylor RS, Lane DR, Ladinsky MS, Weisz JA, Howell KE. GMx33: a novel family of trans-Golgi proteins identified by proteomics. Traffic. 2000;1:963–75. doi: 10.1111/j.1600-0854.2000.11206.x.PubMedGoogle Scholar
  7. 7.
    Scott KL, Kabbarah O, Liang MC, Ivanova E, Anagnostou V, Wu J, Dhakal S, Wu M, Chen S, Feinberg T, Huang J, Saci A, Widlund HR, Fisher DE, Xiao Y, Rimm DL, Protopopov A, Wong KK, Chin L. GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature. 2009;459:1085–90. doi: 10.1038/nature08109.PubMedCrossRefGoogle Scholar
  8. 8.
    Scott KL, Chin L. Signaling from the Golgi: mechanisms and models for Golgi phosphoprotein 3-mediated oncogenesis. Clin Cancer Res. 2010;16:2229–34. doi: 10.1158/1078-0432.CCR-09-1695.PubMedCrossRefGoogle Scholar
  9. 9.
    Li H, Guo L, Chen SW, Zhao XH, Zhuang SM, Wang LP, Song LB, Song M. GOLPH3 overexpression correlates with tumor progression and poor prognosis in patients with clinically N0 oral tongue cancer. J Transl Med. 2012;10:168. doi: 10.1186/1479-5876-10-168.PubMedCrossRefGoogle Scholar
  10. 10.
    Fang W, Li X, Jiang Q, Liu Z, Yang H, Wang S, Xie S, Liu Q, Liu T, Huang J, Xie W, Li Z, Zhao Y, Wang E, Marincola FM, Yao K. Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China. J Transl Med. 2008;6:32. doi: 10.1186/1479-5876-6-32.PubMedCrossRefGoogle Scholar
  11. 11.
    Tu L, Liu Z, He X, He Y, Yang H, Jiang Q, Xie S, Xiao G, Li X, Yao K, Fang W. Over-expression of eukaryotic translation initiation factor 4 gamma 1 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma. Mol Cancer. 2010;9:78. doi: 10.1186/1476-4598-9-78.PubMedCrossRefGoogle Scholar
  12. 12.
    Liu Z, Li L, Yang Z, Luo W, Li X, Yang H, Yao K, Wu B, Fang W. Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma. BMC Cancer. 2010;10:270. doi: 10.1186/1471-2407-10-270.PubMedCrossRefGoogle Scholar
  13. 13.
    Zhu X-D, Zhang J-B, Zhuang P-Y, Zhu H-G, Zhang W, Xiong Y-Q, Wu W-Z, Wang L, Tang Z-Y, Sun H-C. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol. 2008;26:2707–16. doi: 10.1200/JCO.2007.15.6521.PubMedCrossRefGoogle Scholar
  14. 14.
    Kelly K, Crowley J, Bunn Jr PA, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001;19:3210–8.PubMedGoogle Scholar
  15. 15.
    Hennessy BT, Hanrahan EO, Daly PA. Non-Hodgkin lymphoma: an update. Lancet Oncol. 2004;5:341–53.PubMedCrossRefGoogle Scholar
  16. 16.
    Wang JH, Chen XT, Wen ZS, Zheng M, Deng JM, Wang MZ, Lin HX, Chen K, Li J, Yun JP, Luo RZ, Song LB. High expression of GOLPH3 in esophageal squamous cell carcinoma correlates with poor prognosis. Plos One. 2012;7:e45622. doi: 10.1371/journal.pone.0045622.PubMedCrossRefGoogle Scholar
  17. 17.
    Zhou J, Xu T, Qin R, Yan Y, Chen C, Chen Y, Yu H, Xia C, Lu Y, Ding X, Wang Y, Cai X, Chen J. Overexpression of Golgi phosphoprotein-3 (GOLPH3) in glioblastoma multiforme is associated with worse prognosis. J Neurooncol. 2012;110:195–203. doi: 10.1007/s11060-012-0970-9 Google Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2012

Authors and Affiliations

  1. 1.Department of Hepatobiliary Pancreatic CenterThe Third Hospital Affiliated to Nantong UniversityWuxiChina
  2. 2.Department of General SurgeryNorthern Jiangsu People’s HospitalYangzhouChina

Personalised recommendations